Literature DB >> 20100874

Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.

Judit Morello1, Vincent Soriano, Pablo Barreiro, José Medrano, Antonio Madejón, Gema González-Pardo, Inmaculada Jiménez-Nácher, Juan González-Lahoz, Sonia Rodríguez-Novoa.   

Abstract

The influence of ribavirin trough concentrations (RBV C(trough)) on the risk of hepatitis C virus (HCV) relapse was retrospectively analyzed in 99 HIV-HCV-coinfected patients who achieved end-of-treatment response with pegylated alpha interferon plus weight-based RBV. The independent predictors (odds ratio [OR] [95% confidence interval (CI)]) of HCV relapse were RBV plasma C(trough) of <2.5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20100874      PMCID： PMC2849370          DOI： 10.1128/AAC.01399-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

Authors:  Firouzé Bani-Sadr; Lise Denoeud; Patrice Morand; Françoise Lunel-Fabiani; Stanislas Pol; Patrice Cacoub; Christian Perronne; Fabrice Carrat
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

2.  Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.

Authors:  Ana Lucía Rendón; Marina Núñez; Miriam Romero; Pablo Barreiro; Luz Martín-Carbonero; Javier García-Samaniego; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Vincent Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

3.  Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

Authors:  Esther Voigt; Christian Schulz; Gerd Klausen; Joerg Goelz; Stefan Mauss; Guenther Schmutz; Heiko Jessen; Lutwin Weitner; Antonius Mutz; Dietmar Schranz; Juergen K Rockstroh
Journal:  J Infect       Date:  2005-11-02       Impact factor: 6.072

Review 4.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

5.  Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.

Authors:  Alessandra Mangia; Nicola Minerva; Donato Bacca; Raffaele Cozzolongo; Giovanni L Ricci; Vito Carretta; Francesco Vinelli; Gaetano Scotto; Giuseppe Montalto; Mario Romano; Giuseppe Cristofaro; Leonardo Mottola; Fulvio Spirito; Angelo Andriulli
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

7.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

8.  Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.

Authors:  Marina Núñez; Ana Mariño; Angel Mariño; Celia Miralles; Miguel A Berdún; Julio Sola; Juan Jose Hernandez-Burruezo; Maria Jose Galindo; Pablo Barreiro; Luz Martin-Carbonero; Vincent Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

9.  Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.

Authors:  Judit Morello; Sonia Rodríguez-Nóvoa; Ana L Rendon Cantillano; Gema González-Pardo; Inmaculada Jiménez; Vincent Soriano
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

10.  Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.

Authors:  B Ramos; M Núñez; A Rendón; M A Berdún; E Losada; I Santos; S Echevarría; A Ocampo; C Miralles; P Arazo; P Barreiro; M Romero; P Labarga; J M Guardiola; J Garcia-Samaniego; V Soriano
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728
View more
  7 in total

1.  Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Authors:  Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong
Journal:  Can J Hosp Pharm       Date:  2012-03

2.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

Review 3.  A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Authors:  Girish S Naik; Manoj G Tyagi
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

4.  Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.

Authors:  Manel Aouri; Darius Moradpour; Matthias Cavassini; Thomas Mercier; Thierry Buclin; Chantal Csajka; Amalio Telenti; Andri Rauch; Laurent A Decosterd
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

5.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.

Authors:  Jacques Friborg; Nannan Zhou; Zhou Han; Xiaoyan Yang; Paul Falk; Patricia Mendez; Fiona McPhee
Journal:  Infect Dis Ther       Date:  2014-12-17

7.  Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.

Authors:  Helen Kovari; Stefan Russmann; Bruno Ledergerber; Daniel Müller; Margalida Rotger; Pablo Velli; Matthias Cavassini; Juan Ambrosioni; Andrea Bregenzer; Marcel Stöckle; Enos Bernasconi; Andri Rauch; Roberto F Speck
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.